This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this multicenter phase I trial are to determine the maximum tolerated dose, to obtain pharmacokinetic studies, to describe treatment-related and dose-limiting toxicities, and to describe the anti-leukemia activity of SB-715992 given as an infusion in patients with acute leukemia. SB-715992 is a polycyclic, nitrogen-containing heterocycle also possessing amide and amine functions that acts by inhibiting a novel molecular target for anticancer therapy, the mitotic kinesin spindle protein (KSP) (also called HsEg5). SB-715992 is a potent inhibitor of cell growth, and causes cells to arrest in mitosis with unseparated centrosomes and monopolar mitotic spindles following both in vitro and in vivo treatment. SB-715992 demonstrates efficacy, complete response (CR) and partial responses (PR) on an intermittent schedule in a spectrum of preclinical tumor models, including models considered chemo-refractory. In two ongoing phase I studies of SB-715992 in patients with solid tumors, the drug has been well tolerated. This study will enroll patients 18 years and older with relapsed acute leukemia and patients with de novo acute leukemia who are not candidates for standard aggressive induction regimens due to advanced age or serious comorbid medical conditions. The study will utilize an accelerated titration design as outlined in the protocol. Escalated doses will be given intravenously over one hour for 3 consecutive days, every 21 days for a maximum of 3 cycles. Serum samples for pharmacokinetic studies will be obtained. Correlative laboratory studies will include evaluation of pretreatment bone marrow aspirates for expression of Beta-tubulin and KSP. Peripheral mononuclear cells and bone marrow aspirates for studies of cytoskeleton morphology and in situ apoptosis during treatment. Results of investigational laboratory studies will be correlated with clinical response. Patients who achieve a complete or partial response or stable disease will be eligible to receive up to 4 additional consolidation courses of treatment every 3 weeks or until bone marrow aplasia is achieved (defined as bone marrow cellularity less than or equal to 5% and/or less than or equal to 5% marrow blasts). The study will enroll a total of 30 subjects at all sites. 15 subjects are expected at this site.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000080-44
Application #
7378067
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Project Start
2006-04-01
Project End
2007-03-31
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
44
Fiscal Year
2006
Total Cost
$27,873
Indirect Cost
Name
Case Western Reserve University
Department
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Randis, Tara M; Rice, Madeline Murguia; Myatt, Leslie et al. (2018) Incidence of early-onset sepsis in infants born to women with clinical chorioamnionitis. J Perinat Med 46:926-933
Clark, Erin A S; Weiner, Steven J; Rouse, Dwight J et al. (2018) Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth. Am J Perinatol 35:1012-1022
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Saade, G R; Thom, E A; Grobman, W A et al. (2018) Cervical funneling or intra-amniotic debris and preterm birth in nulliparous women with midtrimester cervical length less than 30 mm. Ultrasound Obstet Gynecol 52:757-762
Inker, Lesley A; Grams, Morgan E; Levey, Andrew S et al. (2018) Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis :
Juraschek, Stephen P; Miller 3rd, Edgar R; Appel, Lawrence J (2018) Orthostatic Hypotension and Symptoms in the AASK Trial. Am J Hypertens 31:665-671
Juraschek, Stephen P; Appel, Lawrence J; Miller 3rd, Edgar R (2017) Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. Am J Hypertens 30:871-875
O'Toole, John F; Bruggeman, Leslie A; Madhavan, Sethu et al. (2017) The Cell Biology of APOL1. Semin Nephrol 37:538-545
Chen, Teresa K; Tin, Adrienne; Peralta, Carmen A et al. (2017) APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. Clin J Am Soc Nephrol 12:1771-1777
Catalano, Patrick M; Shankar, Kartik (2017) Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. BMJ 356:j1

Showing the most recent 10 out of 753 publications